

University of Dundee

DOCTOR OF PHILOSOPHY

Investigation of BACE1 as a stress-induced regulator of neuronal metabolism

Findlay, John Alexander

Award date:
2014

Awarding institution:
University of Dundee

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Contents

Declarations	VI
Acknowledgements	VIII
Summary	IX
List of Figures	XI
List of Tables	XV
Abbreviations	XVI

Chapter 1 – Introduction

1.1	Dementia	2
1.2	Alzheimer's disease	3
1.2.1	Background	3
1.2.2	NFT pathology	5
1.2.3	Amyloid- β ($A\beta$) Pathology and the Cascade Hypothesis	5
1.3	Precipitating Factors in AD	6
1.3.1	Genetic Factors in AD	7
1.3.2	Lifestyle Related Risk Factors	8
1.3.2.1	Cardiovascular Disease/Ischemia	8
1.3.2.2	Hypertension	9
1.3.2.3	Plasma Lipid Levels	9
1.3.2.4	Obesity	10
1.3.2.5	Type 2 Diabetes Mellitus (T2DM)	11
1.4	Cellular Drivers of Sporadic AD	12
1.4.1	Concerted Actions of the Hallmark Pathologies	13
1.4.2	Oxidative Stress	14
1.4.3	Mitochondrial Dysfunction	15
1.4.5	Bioenergetic Changes	16
1.4.6	Hypometabolism	17
1.4.7	Calcium deregulation	19
1.4.8	Synapse Loss	20
1.5.1	Amyloid Precursor Protein (APP)	20
1.5.2	APP processing	21
1.6	Characterisation of the Secretase Enzymes	23
1.7	BACE1 Structure, Trafficking and Regulation	26
1.8	Physiological Roles of BACE1 and APP	32
1.8.1	APP	32
1.8.1.1	Trophic Effects	33
1.8.1.2	Cell Adhesion	34
1.8.1.3	Receptor Function	34
1.8.2	BACE1	34
1.9	Modulation of the BACE1-APP Axis by Cellular Stress	36
1.9.1	Oxidative Stress	36
1.9.2	Metabolic Stress	38
1.9.3	Lipid Stress	40
1.10	Activity-induced Change in APP Processing	42
1.11	Neuronal Metabolism and Activity	44

1.12	Role for BACE1 in Metabolism	45
1.13	Project Aims	45

Chapter 2 – Materials and Methods

2.1	General	48
2.1.1	Chemicals	48
2.1.2	Statistical Analysis	48
2.2	Cell Culture	48
2.2.1	SH-SY5Y Cells	49
2.2.2	Additional Culture Media Supplements	51
2.2.3	Cell Treatments	51
2.2.3.1	Stress Treatments	51
2.2.3.2	Inhibitor and Other Treatments	51
2.3	Lysate Preparation	52
2.3.1	Cell Lysates	52
2.3.2	Tissue Lysates	52
2.3.3	Protein Content Determination	53
2.3.4	Supernatant Lysates	53
2.4	Western Blotting	54
2.4.1	SDS-PAGE	54
2.4.2	Hofester self-poured	55
2.4.3	Transfer to Nitrocellulose	56
2.4.4	Immuno-blotting	57
2.4.5	Analysis	57
2.6	2-Deoxyglucose Uptake Assay	58
2.7	¹⁴ C-Glucose Oxidation Assays	59
2.8	Seahorse XF24 Analyser	60
2.8.1	Cellular Respiratory Control (CRE) Experiments	61
2.8.2	Glycolysis Stress Test	61
2.9	Activity Assays	62
2.9.1	BACE1 Activity Determination	62
2.9.2	Cellular Metabolism Assay	63
2.9.2.1	Pyruvate Dehydrogenase Activity	63
2.9.2.2	Isocitrate Dehydrogenase Activity	64
2.9.2.3	Alpha-Ketoglutarate Dehydrogenase	65
2.9.2.4	NAD ⁺ /NADH Ratio Assay	66
2.9.2.5	Fumarase Specific Activity Assay	67
2.9.3	Cell Death Assay	69

Chapter 3 – Effect of Cellular Stress on BACE1 and APP Processing

3.1	Introduction	72
3.1.1	Effect of Acute Cellular Stress on BACE1 and APP Processing	72
3.2	Results	75
3.2.1.1	Acute Cellular Stress Treatment Increases BACE1 and APP Protein and BACE1 Activity levels	75
3.2.1.2	Effect on APP Protein Level	82

3.2.2	Acute Stress Treatment Results in Prolonged Increases in BACE1 Protein Level and Activity	82
3.2.3	Chronic Mitochondrial Inhibition Results in Concerted Increases in BACE1 and APP Protein Expression	85
3.2.4	Recurrent Low Glucose Exposure Increases BACE1 and Decreases APP Protein Levels	90
3.2.5	Fatty Acid Treatment and High Fat Diet Significantly Increase BACE1 and APP Protein Levels	91
3.3	Discussion	99
3.3.1	Acute cellular Stress Fundamentally Enhances BACE1-Mediated APP Cleavage via Different Mechanisms	99
3.3.2	Differential Mitochondrial Inhibition Induces Altered Temporal Induction of BACE1 and APP Protein Expression	100
3.3.3	Increased BACE1 Expression Following Cellular Stressors May Involve a Number of Mechanistic Alterations	102
3.3.4	Impact of Oxidant treatment of SH-SY5Y _{APP^{swe}} Cells on BACE1 Protein Expression	105
3.3.5	Control of BACE1 by eIF2 α Kinases and Their Role in AD Pathogenesis	106
3.3.6	Potential Role of GCN2 in AD	108
3.3.7	PERK Activity in AD Progression	109
3.3.8	Linking Oxidative Stress and PKR as Mediators of AD Dysfunction	109

Chapter 4 – Effect of APP Processing Manipulation on Glucose Uptake in SH-SY5Y Cells

4.1	Introduction	114
4.1.1	Glucose Transport to the Brain	114
4.1.2	Insulin-stimulated Glucose Uptake	115
4.1.3	Role of AMPK in Glucose Uptake	116
4.1.4	Insulin Signalling, Glucose Uptake and BACE1	118
4.2	Results	120
4.2.1	2-Deoxyglucose Uptake Profile of the SH-SY5Y cell line	120
4.2.2	BACE1 Overexpression Significantly Reduces Basal and Maximal 2DG Uptake	122
4.2.3	Reduced Glucose Uptake Following BACE1 Overexpression is dependent upon the secretase activity Of BACE1	125
4.2.4	Inhibition of APP Secretase Proteins Significantly Alters 2-DG Uptake	132
4.2.5	Altered 2-DG Uptake Involves an Extracellular Factor	132
4.2.6	Manipulation of APP Metabolism Blunts Insulin-stimulated 2-DG Uptake	138
4.2.7	BACE1 Overexpression Blunts AMPK Protein Expression And Activity in SH-SY5Y cells	140
4.3	Discussion	146
4.3.1	Manipulation of APP Processing Significantly Alters Glucose Uptake in SH-SY5Y Cells	146
4.3.2	BACE1-mediated Regulation of CREB Signalling	147

4.3.3	Promotion of sAPP α Production and Glucose Uptake	148
4.3.4	Insulin Resistance as a Driver of AD pathogenesis	151

Chapter 5 – Effect of BACE1 Overexpression on Neuronal Substrate Use in SH-SY5Y Cells

5.1	Introduction	156
5.1.1	Central Metabolism	156
5.1.2	Neuronal Glucose Metabolism	157
5.1.3	NAD ⁺ and SIRT1 as Regulators of Ageing and AD	160
5.2	Results	164
5.2.1	BACE1 Overexpression Impairs Glucose Use in SH-SY5Y cells	164
5.2.2	BACE1 Overexpression Alters Respiration Towards Aerobic Glycolysis in SH-SY5Y Cells	167
5.2.3	BACE1 Overexpression Significantly Increases all Glycolytic Measures in SH-SY5Y Cells	169
5.2.4	BACE1 Overexpression Impairs Lactate Use in SH-SY5Y Cells	173
5.2.5	BACE1-mediated Impairment in Oxidative Phosphorylation Due to Reduced Substrate Delivery to the Mitochondria and not Impaired Functioning	175
5.2.6	Impaired Glucose Oxidation in SH-SY5Y Cells can be Partially Reversed by Treatment with Dichloroacetate	180
5.2.7	BACE1 Overexpression Results in Impaired TCA Cycle Enzyme Function in SH-SY5Y Cells	183
5.2.8	Impaired Glucose Oxidation Following BACE1 Overexpression can be Effectively Attenuated by α -Lipoic Acid Supplementation in SH-SY5Y Cells	191
5.2.9	BACE1-mediated impairment in Oxidative Glucose Use can be Effectively Attenuated by Ketone Body Supplementation	193
5.2.10	BACE1 Overexpression Significantly Alters the Balance of Oxidised and Reduced Nicotinamide Dinucleotide and Alters SIRT1-PGC1 α Signalling in SH-SY5Y Cells	197
5.3	Discussion	201
5.3.1	Hypometabolism in AD	201
5.3.2	Altered Mitochondrial Function Following BACE1 Overexpression	202
5.3.3	BACE1-mediated Regulation of Substrate Flux	204
5.3.4	Potential Benefits of Ketone Body and Alpha-Lipoic Acid Supplementation in AD	209
5.3.5	BACE1-induced Changes in NAD ⁺ and SIRT1	212
5.3.6	BACE1-dependent Alterations to the PGC1 α -SIRT1-AMPK Energy Sensing Network	214

Chapter 6 – Final Conclusions

6.1	Role of BACE1 in Sporadic AD and Other Disorders	218
6.2	Regulation of BACE1 and APP by Cellular Stress	219

6.3	BACE1 as a Regulator of Glucose Uptake	220
6.4	BACE1 as a Regulator of Neuronal Substrate Use	221
6.5	BACE1-mediated Change in SIRT1 Signalling	222
6.6	Potential for Reversal of BACE1-Dependent Metabolic Changes	223
6.7	Physiological Relevance	225
<u>Appendix I – Seahorse Characterisation of SH-SY5Y Cells</u>		227
<u>Chapter 8 – References</u>		232
<u>Publications Arising During this Project</u>		272

Candidate's Declaration

I hereby declare that all results described in this thesis, unless otherwise stated, are entirely my own work. I further state that the composition of this thesis was performed by myself and none of the material has been submitted for any other degree. Lastly, I verify that all sources have been appropriately cited. The work was carried out in the Medical Research Institute, University of Dundee, under the supervision of Professor M. L. J. Ashford.

John Alexander Findlay

Supervisor's Declaration

I certify that John Alexander Findlay has completed 8 terms of experimental research and has fulfilled the conditions of Ordinance 39, University of Dundee, such that he is eligible to submit the following thesis in application for the degree of Doctor of Philosophy.

Professor M. L. J. Ashford

Acknowledgements

Firstly I would like to thank my supervisor, Professor Mike Ashford for the opportunity to undertake this project as well as his support and input throughout its duration.

I also wish to thank all Ashford lab members, past and present, in particular the current crop of PhD students (Geoff, Susan, Fiona, David, Polly and Adonis), for making the days in the lab more enjoyable. I have also been extremely fortunate to receive excellent Post Doc guidance and training during my PhD. For that, I need to thank Paul, Ritchie, Gemma and particularly “Hambo” for all of the invaluable teaching and support during his time in the lab and beyond.

I must also thank everyone at Alzheimer’s Research UK for firstly funding the project but also for giving me the opportunity to communicate my work at Conferences and arranging radio interviews to discuss my research with the public.

In addition, thanks to all of my family and friends for understanding the not being around as much, it should get better now. Finally, I want to thank Lizzie for all of her support, through good times and stressful and for always being there for me (even when I probably don’t deserve it).

Summary

Alzheimer's disease (AD) is the most common cause of dementia, accounting for around 60-70% of cases. AD encompasses large-scale neuronal loss, resulting in progressive memory and other cognitive decline. Presently, there is no cure for dementia and in light of the ageing population demographic, this represents a clear unmet medical and socioeconomic challenge Worldwide. Much of the current AD research focuses on studying the brain once hallmark amyloid- β ($A\beta$) plaque and neurofibrillary tangle pathologies have presented. However their appearance is extremely end stage and to date, any therapeutic interventions aimed at alleviating them having failed to halt symptoms progression. It may therefore be beneficial to look for earlier changes, with metabolic and oxidative stress events as well as reduced cerebral metabolism thought to occur early on in disease progression.

Evidence from rare, familial AD cases suggests a causative role for $A\beta$ in AD pathogenesis. For this reason, the enzyme β -site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1), the rate-limiting step in $A\beta$ production is currently of great therapeutic interest. With the prevailing view being that reducing BACE1 levels will be beneficial in AD, there remains a need to better understand the physiological roles of BACE1 to avoid potential side effects of BACE1 inhibition.

Herein is presented data showing that, in agreement with the previous literature, BACE1 is fundamentally regulated by cell stress. Notably, both acute and prolonged bouts of oxidative and metabolic stress result in significant increases in BACE1 and

APP protein expression. These changes also result in a shift in APP metabolism, with amyloidogenic processing of APP predominating during times of stress.

It has also been shown that chronic elevation of BACE1 and/or manipulation of APP processing can alter cellular glucose uptake and use. These changes were determined through the use of radiolabelled substrate uptake and oxidation as well as extracellular flux assays. These data highlighted a fundamental shift in cellular metabolism, with aerobic glycolysis being utilised over oxidative metabolism of glucose. These changes were later shown to come as a result of metabolic lesions, which acted to impair substrate delivery to the electron transport chain of the mitochondria. Taken together, these data show that overexpression of the AD-associated protein BACE1 phenocopies a number of the earliest detectable changes observed in the brains of people who later develop AD.

Finally, these data highlighted the potential importance of a number of novel pathways (Sirtuin, AMP-activated protein kinase, and peroxisome proliferator-activated receptor- γ coactivator signalling) that may underlie these changes and offer therapeutic avenues for earlier and more targeted treatment to halt AD progression.

List of Figures**Chapter 1 – Introduction**

- | | | |
|-----|---|----|
| 1.1 | Representative image of amyloid plaque and tau tangle | 4 |
| 1.2 | Schematic diagram of APP processing | 22 |

Chapter 3 – Effect of Cellular Stress on BACE1 and APP Processing

- | | | |
|------|---|-----|
| 3.1 | Acute treatment of SH-SY5Y _{APP^{swe}} cells with the protein synthesis inhibitor anisomycin or the lipid second messenger ceramide does not alter BACE1 protein levels | 76 |
| 3.2 | Acute (1-hour) treatment of SH-SY5Y _{APP^{swe}} cells with anisomycin and ceramide significantly increases BACE1 activity | 77 |
| 3.3 | Acute (4-hour) treatment of SH-SY5Y _{APP^{swe}} cells with anisomycin and ceramide significantly increases BACE1 activity | 79 |
| 3.4 | Acute mitochondrial inhibition and oxidative stress significantly increase BACE1 protein levels in SH-SY5Y _{APP^{swe}} cells | 80 |
| 3.5 | Acute mitochondrial inhibition and oxidative stress significantly increases sAPP β release from SH-SY5Y _{APP^{swe}} cells | 81 |
| 3.6 | 4-hour but not 1-hour incubation with mitochondrial inhibitors and H ₂ O ₂ increases BACE1 activity in SH-SY5Y _{APP^{swe}} cells | 83 |
| 3.7 | Acute stress treatment results in lowered APP protein expression in SH-SY5Y _{APP^{swe}} cells | 84 |
| 3.8 | Increases in BACE1 protein levels and sAPP β release following acute mitochondrial inhibition and oxidative stress in SH-SY5Y _{APP^{swe}} are prolonged upon washout | 86 |
| 3.9 | Prolonged mitochondrial inhibition of SH-SY5Y _{APP^{swe}} cells results in significant increases in BACE1 and APP protein expression | 88 |
| 3.10 | Prolonged stimulation of aerobic glycolysis significantly increases BACE1 and APP protein levels in SH-SY5Y _{APP^{swe}} cells | 89 |
| 3.11 | Recurrent low glucose exposures result in significant changes in BACE1 and APP protein levels in GT1-7 cells | 92 |
| 3.12 | Chronic fatty acid treatment significantly increases BACE1 and APP protein levels in SH-SY5Y _{APP^{swe}} cells | 93 |
| 3.13 | Acute fatty acid exposure stimulates BACE1 and APP protein expression in SH-SY5Y _{APP^{swe}} cells | 95 |
| 3.14 | High fat diet (HFD) feeding in mice significantly enhances BACE1 and APP protein expression in the hippocampus | 97 |
| 3.15 | High fat diet (HFD) feeding of mice results in increased stress-activated protein kinase (SAPK) activation in the hippocampus | 98 |
| 3.16 | Schematic diagram showing integration of eIF2 α kinase signals | 112 |

Chapter 4 – Effect of APP Processing Manipulation on Glucose Uptake in SH-SY5Y Cells

4.1	Schematic diagram showing the convergent insulin and muscle contraction pathways on GLUT4 translocation	117
4.2	³ H-2-Deoxyglucose (2DG) uptake profile in SH-SY5Y cells	121
4.3	Stable BACE1 overexpression significantly alters APP processing in SH-SY5Y cells	123
4.4	BACE1 overexpression significantly impairs basal and maximal ³ H-2DG uptake in SH-SY5Y cells	124
4.5	BACE1-mediated impairment in ³ H-2DG uptake can be attenuated by BACE1 secretase activity inhibition in SH-SY5Y cells	126
4.6	Stable overexpression of BACE1 and mBACE1 significantly alters APP processing in SH-SY5Y cells	127
4.7	BACE1-mediated impairment in ³ H-2DG uptake dependent upon BACE1 secretase activity in SH-SY5Y cells	129
4.8	Overexpression of wild type and Swedish mutation harbouring APP resulted in increased, but altered APP cleavage production generation in SH-SY5Y cells	130
4.9	Overexpression of wild type APP (APP ^{wt}) and APP harbouring the Swedish mutation (APP ^{swe}) significantly alters 2DG uptake in SH-SY5Y cells	131
4.10	Inhibition of APP-cleaving enzymes impacts 2DG uptake in SH-SY5Y cells	133
4.11	BACE1-mediated reduction in 2DG uptake in SH-SY5Y cells involves an extracellular factor	135
4.12	sAPP α treatment significantly increases glucose uptake and protein kinase B (PKB) phosphorylation in SH-SY5Y cells	137
4.13	BACE1 and APP(wt and Swe) overexpressing cells display blunted insulin-stimulated 2DG uptake in SH-SY5Y cells	139
4.14	BACE1 overexpressing cells retain their insulin-stimulated phosphorylation of serine 473 of PKB	141
4.15	BACE1 overexpressing cells display diminished insulin-stimulated phosphorylation of threonine 308 of PKB	142
4.16	Stable BACE1 overexpression enhances MAPK signalling in SH-SY5Y cells	143
4.17	BACE1 overexpression significantly blunts AMPK signalling in SH-SY5Y cells	145
4.18	Hypothetical model showing potential points of interaction for APP cleavage products in insulin-mediated glucose uptake	154

Chapter 5 – Effect of BACE1 Overexpression on Neuronal Substrate Use on Neuronal Substrate Use in SH-SY5Y cells

5.1	Schematic diagram of the glycolytic pathway	159
5.2	Schematic diagram of the TCA cycle and electron transport chain	161
5.3	BACE1 overexpression significantly impairs glucose oxidation in SH-SY5Y cells	165
5.4	Absence of BACE1-mediated glucose oxidation impairment following overexpression of BACE1 mutant devoid of secretase activity in SH-SY5Y cells	166
5.5	BACE1 overexpression significantly alters cellular respiration in the presence of 2.5mM glucose in SH-SY5Y cells	168
5.6	BACE1 overexpression significantly enhances the rate of glycolysis in SH-SY5Y cells	170
5.7	BACE1 overexpression leaves SH-SY5Y cells more susceptible to cell death during increased energy	172
5.8	BACE1 overexpression significantly impairs cellular lactate use in SH-SY5Y cells	174
5.9	BACE1 overexpression does not significantly alter ATP-linked, mitochondrial leak or non-mitochondrial oxygen consumption in SH-SY5Y cells	177
5.10	BACE1 overexpression does not significantly alter cellular reserve capacity for glucose metabolism in SH-SY5Y cells	178
5.11	BACE1 overexpression significantly impairs pyruvate dehydrogenase function in SH-SY5Y cells	179
5.12	BACE1-mediated impairment in glucose oxidation is partially reversed following dichloroacetate treatment in SH-SY5Y cells	181
5.13	BACE1 overexpressing SH-SY5Y cells display enhance phosphorylation of the e1 α subunit of PDH under control and DCA-treated conditions	182
5.14	BACE1 overexpression impairs α -ketoglutarate dehydrogenase activity in SH-SY5Y cells	184
5.15	BACE1 overexpression impairs isocitrate dehydrogenase activity in SH-SY5Y cells	186
5.16	BACE1 overexpression induces reductive glutamine metabolism in SH-SY5Y cells	188
5.17	BACE1 overexpression results in no change to fumarase specific activity in SH-SY5Y cells	190
5.18	BACE1-mediated impairment in glucose oxidation fully reversed by α -lipoic acid supplementation in SH-SY5Y cells	192
5.19	BACE1-mediated impairment in glucose oxidation effectively attenuated by ketone body supplementation	195
5.20	Enhanced ketone body use following BACE1 overexpression due to reduced BAD protein levels	196
5.21	BACE1 overexpression significantly alters nicotinamide adenine dinucleotide (NAD) redox status in SH-SY5Y cells	198
5.22	BACE1 overexpression significantly alters SIRT1-PGC1 protein levels in SH-SY5Y cells	200

Appendix I – Seahorse Characterisation of SH-SY5Y Cells

A1.1	Measurement of oxygen consumption rate (OCR) by the Seahorse XF24	228
A1.2	Cell titration assay of SH-SY5Y cells	229
A1.3	Modulation of OCR by the addition of various mitochondria Modulating drugs	230
A1.4	Shortcoming of standard Mito Stress test protocol in the present Cell model	231

List of Tables**Chapter 2 – Materials and Methods**

2.1	Cell transfection components	50
2.2	SDS-PAGE gel composition	55
2.3	Primary antibody table	58
2.4	Solutions table	69-70

Abbreviations

All abbreviations are defined at first mention in the text. For the convenience of the reader, some of the more commonly used abbreviations are defined below in alphabetical order.

α -KGDH	Alpha-ketoglutarate dehydrogenase
A β	β -amyloid
ACC	Acetyl-CoA carboxylase
AD	Alzheimer's disease
ADAM	A disintegrin and metalloproteinase
ADP	Adenosine diphosphate
AMP	Adenosine monophosphate
AMPK	AMP-activated protein kinase
APP	Amyloid precursor protein
ATF4	Activating transcription factor 4
BBB	Blood brain barrier
CD38	Cluster of differentiation 38
CMR	Cerebral metabolic rate
CoA	Coenzyme A
DAPT	N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenylglycine-1,1-dimethylethyl ester
DCA	Dichloroacetate
2-DG	2-Deoxy-D-glucose
DNP	Dinitrophenol
ECAR	Extracellular acidification rate
eIF2 α	Eukaryotic initiation factor 2 α
ETC	Electron transport chain
FCCP	Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone
fMRI	Functional magnetic resonance imaging
GCN2	General non-derepressible kinase 2
GLUT	Glucose transporter
HFD	High fat diet
HIF1 α	Hypoxia-inducible factor 1 α
HK	Hexokinase
4-HNE	4-Hydroxynonenal
H ₂ O ₂	Hydrogen peroxide
IDH	Isocitrate dehydrogenase
ISR	Integrated stress response
JNK/SAPK	c-Jun N-terminal kinase/Stress activated protein kinases
MAPK	Mitogen-activated protein kinases
NAD	Nicotinamide adenine dinucleotide
3-NP	3-Nitropropionic acid
OCR	Oxygen consumption rate
PARP1	Poly ADP-ribose polymerase 1
PDH	Pyruvate dehydrogenase
PDK	Pyruvate dehydrogenase kinase
PERK	PKR-like ER kinase
PET	Positron emission tomography
PFK	Phosphofructokinase

XVII

PI ₃ K	Phosphoinositide 3-kinase
PKB	Protein kinase B
PKR	Protein kinase R
PPP	Pentose phosphate pathway
RH	Recurrent hypoglycemia
sAPP α/β	Soluble amyloid precursor protein α/β
SEM	Standard error of the mean
SIRT	Sirtuin
TAPI-1	N-(R)-[2-(Hydroxyaminocarbonyl)methyl]-4-methylpentanoyl-L-naphthylalanyl-L-alanine
TCA cycle	Tricarboxylic acid cycle
uORK	Upstream open reading frames
UTR	Untranslated region